Bayer has partnered with private equity group Apollo to set up a new entity that will handle its long-acting contraceptive ...
The demise of the two programmes still leaves Roche with one Huntington's candidate, the gene therapy RG6662, which is in a ...
The non-profit Drugs for Neglected Diseases initiative (DNDi) has joined forces with pharma group Serum Institute of India ...
mResvia has been approved in the EU since 2024 to protect adults aged 60 years and older against lower respiratory tract ...
End-of-life decisions rarely happen in a calm or orderly way. They often come quickly, emotionally, and under pressure.
Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in ...
Alector has confirmed that an alliance with GSK to develop two drug candidates for dementia has been terminated in the wake ...
Shares in AstraZeneca were trading down more than 8% this morning after it revealed that its transthyretin amyloidosis (ATTR) ...
B inhibitor Jascayd (nerandomilast) has been cleared as a twice-daily, oral therapy for adults with IPF as well as ...
The drugmaker – which was known as Mallinckrodt beforemerging with Endo and rebranding as Keenova last year – said that ...
The EMA's human medicines committee has started a review of oral complement C5 inhibitor Tavneos, prompted by information that the regulator says raises questions about the integrity of the data from ...
Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgA nephropathy (IgAN) that will compete with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results